Search - tctmd.com

Displaying 221 - 240 of 241

Sort: Relevancy | Date

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Conference News ESC Heart Failure 2019

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

Shelley Wood

May 28, 2019

News Conference News ESC Heart Failure 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

Shelley Wood

May 26, 2019

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Shelley Wood

May 09, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Shelley Wood

February 26, 2019

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Todd Neale

October 02, 2018

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Todd Neale

August 27, 2018

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

Advertisement

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Top News in Heart Failure: 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content